China’s Endoscopic Ultrasonography (EUS) Market, estimated at US$ XX billion in 2024 and 2025, is projected to grow steadily at a CAGR of XX% from 2025 to 2030, ultimately reaching US$ XX billion by 2030.
The global endoscopic ultrasonography market was valued at $1.28 billion in 2023, is estimated at $1.37 billion in 2024, and is projected to reach $1.93 billion by 2029, growing at a CAGR of 7.1%.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=19121066
Drivers
The China Endoscopic Ultrasonography (EUS) Market is experiencing significant growth, primarily driven by the rising prevalence of gastrointestinal and pulmonary diseases, notably cancers such as pancreatic, esophageal, and lung cancer, which require high-precision diagnostic and staging procedures. EUS offers a minimally invasive alternative for detailed imaging and guided tissue sampling (fine-needle aspiration or biopsy), making it an indispensable tool in modern oncology and gastroenterology workflows. Furthermore, the Chinese government’s commitment to modernizing and expanding healthcare infrastructure, particularly in Tier 2 and Tier 3 cities, is increasing the accessibility and adoption of advanced medical technologies like EUS systems. This is coupled with a growing awareness among patients and medical professionals regarding the benefits of early and accurate disease diagnosis. The increasing clinical adoption of EUS is also being fueled by its expanded therapeutic applications, including drainage procedures and drug delivery, moving beyond purely diagnostic uses. As the disposable income and healthcare spending capacity of the Chinese population continue to rise, the demand for sophisticated diagnostic and therapeutic procedures is accelerating, positioning EUS as a key growth segment in the country’s medical device market. Additionally, favorable regulatory reforms that streamline the approval process for innovative medical devices contribute to market expansion by making advanced EUS technology more readily available.
Restraints
Despite robust growth, the China Endoscopic Ultrasonography (EUS) Market faces several limiting factors. A primary restraint is the high cost associated with EUS equipment, maintenance, and the required specialized, single-use accessories, which poses a financial barrier for smaller hospitals and healthcare facilities, particularly outside of major metropolitan areas. This cost sensitivity can slow down the pace of widespread adoption across the vast healthcare landscape of China. Another significant constraint is the limited availability of highly trained and experienced endoscopists and sonographers proficient in EUS procedures. EUS requires specialized expertise and a steep learning curve, and the current workforce capacity for these procedures is insufficient to meet the rapidly rising demand. Furthermore, the reliance on imported high-end EUS technology from international market leaders creates supply chain vulnerabilities and contributes to the high cost structure. While domestic manufacturers are emerging, they currently lack the market share and technological maturity to significantly lower prices or replace established international brands, perpetuating the high investment threshold. Finally, a lack of standardized clinical guidelines and reimbursement policies across all regions can lead to uncertainty for healthcare providers, making capital investment in EUS equipment riskier and hindering uniform market penetration.
Opportunities
The China Endoscopic Ultrasonography (EUS) Market presents substantial opportunities, largely stemming from technological advancements and market penetration strategies. A major opportunity lies in the burgeoning application of EUS in screening and early detection programs for high-risk populations, particularly for pancreatic and lung cancers, which could dramatically expand the procedure volume. There is immense potential in the integration of Endoscopic Ultrasonography with Artificial Intelligence (AI). AI algorithms can significantly enhance image interpretation, improve diagnostic accuracy, and standardize procedures, thereby addressing the existing restraint of limited expert personnel and accelerating the training of new endoscopists. The shift towards therapeutic EUS, including EUS-guided interventions such as biliary drainage, gastrojejunostomy, and tumor ablation, is opening new, high-value revenue streams beyond traditional diagnostics. Furthermore, a concerted effort to foster domestic manufacturing and innovation in EUS equipment offers an opportunity to introduce more cost-effective, locally tailored systems. This domestic market focus, supported by government mandates to prioritize indigenous medical technology, would reduce reliance on imports and improve affordability. Lastly, expanding the application of EUS to non-oncological conditions, such as inflammatory bowel disease and musculoskeletal disorders, broadens the patient base and utilization potential, driving long-term market growth within China.
Challenges
The China Endoscopic Ultrasonography (EUS) Market faces persistent challenges related to operational scalability and competitive dynamics. A significant challenge is ensuring quality control and standardization of EUS procedures across a highly fragmented healthcare system. Variability in operator expertise and equipment quality can affect diagnostic reliability and patient outcomes, demanding robust regulatory oversight and centralized training programs. The market also contends with intense competition, particularly from established international players like Olympus and Fujifilm, making it difficult for emerging domestic companies to gain significant market share. Furthermore, the technical complexity and delicate nature of EUS equipment and scopes require specialized maintenance and a reliable supply chain for consumables, which remains a logistical challenge, particularly in remote areas. Regulatory hurdles, although improving, can still slow the introduction and diffusion of novel EUS-related technologies and devices, impacting innovation cycles. Finally, the need for continuous professional development and advanced training to keep up with the rapid evolution of EUS technology and its expanding therapeutic applications requires substantial investment from healthcare institutions and professional societies, posing a long-term resource challenge for sustainable market growth.
Role of AI
Artificial Intelligence (AI) is poised to play a transformative role in the China Endoscopic Ultrasonography (EUS) Market by addressing key limitations and boosting efficiency. AI is primarily utilized for image analysis and interpretation, where deep learning algorithms can rapidly and accurately identify lesions, classify tissue types (such as benign versus malignant tumors), and delineate anatomical structures on EUS images. This capability is crucial for standardizing diagnostic accuracy, especially in non-expert hands, and reducing inter-operator variability. In EUS-guided interventions, AI can provide real-time guidance, optimizing needle placement for fine-needle aspiration (FNA) or biopsy and improving the yield of tissue samples, thereby minimizing the need for repeated procedures. Furthermore, AI tools are vital for enhancing the training and education of new endoscopists, offering virtual training simulations and providing instant performance feedback, significantly speeding up the learning curve and quality control. AI can also be integrated into clinical data management to correlate EUS findings with patient histories and genomic data, enabling more comprehensive diagnostic decision support. This focus on AI integration aligns with China’s broader national strategy to adopt “smart healthcare” technologies, ensuring that AI-enhanced EUS becomes a critical component in the future of precise and efficient cancer diagnostics.
Latest Trends
Several dynamic trends are currently shaping the China Endoscopic Ultrasonography (EUS) Market. A significant trend is the expansion of **EUS-Guided Therapeutic Interventions**, moving beyond standard diagnostics to complex procedures like EUS-guided biliary drainage, gastroenterostomy, and tumor ablation, positioning EUS as a minimally invasive therapeutic platform. Another major trend is the accelerated **Integration of Artificial Intelligence (AI)** into EUS systems for real-time image enhancement, automated lesion detection, and diagnostic classification, which is seen as crucial for improving accuracy and overcoming the scarcity of highly specialized experts. There is a growing focus on the development of **Next-Generation EUS Technology**, including high-frequency miniprobes and enhanced Doppler capabilities, which offer superior image resolution and vascular assessment for detailed staging. Furthermore, the market is witnessing a rise in **Domestic Manufacturing and Localization**, with Chinese companies receiving government support to develop competitive EUS platforms, aiming to reduce dependence on costly imported systems and make the technology more accessible to a wider range of hospitals. Finally, the trend toward **Point-of-Care (POC) EUS** solutions is gaining traction, potentially leading to more portable and streamlined devices for use in diverse clinical settings, further driving the widespread adoption of EUS technology across the Chinese healthcare system.